Last reviewed · How we verify
Recombinant Human Thymosin β4 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Recombinant Human Thymosin β4 (Recombinant Human Thymosin β4) — Beijing Northland Biotech. Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant Human Thymosin β4 TARGET | Recombinant Human Thymosin β4 | Beijing Northland Biotech. Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant Human Thymosin β4 CI watch — RSS
- Recombinant Human Thymosin β4 CI watch — Atom
- Recombinant Human Thymosin β4 CI watch — JSON
- Recombinant Human Thymosin β4 alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant Human Thymosin β4 — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-thymosin-4. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab